CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Duvelisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02711852
NCT02711852Phase 2Completed
CompareCT.gov

A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)

SecuraBio·interventional·Posted Mar 17, 2016·Updated Sep 11, 2023

In Brief

A Phase 2 clinical trial evaluating Duvelisib for Hematologic Malignancy. Completed, enrolled 19 participants across 5 sites in 2 countries.

Detailed Summary

This was a long-term, continued treatment study that evaluated the long-term safety, clinical activity, and overall survival (OS) of duvelisib in individuals with hematologic malignancies that were previously treated with duvelisib in a previous sponsor-approved study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Malignancy
CountriesItaly, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 17, 2016
Enrollment StartApr 1, 2016
Primary CompletionMay 4, 2020
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 10.3 years ago

Interventions

Duvelisibdrug

Administered as oral capsules